leflunomide has been researched along with Carcinoma, Squamous Cell in 5 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 78-year-old woman diagnosed with rheumatoid arthritis without a history of skin tumors or immunosuppressive medication, started treatment with leflunomide." | 7.79 | Multiple eruptive keratoacanthomas associated with leflunomide. ( Bouret, AM; Frances, L; Guijarro, J; Leiva-Salinas, Mdel C; Marin, I, 2013) |
| "A 78-year-old woman diagnosed with rheumatoid arthritis without a history of skin tumors or immunosuppressive medication, started treatment with leflunomide." | 3.79 | Multiple eruptive keratoacanthomas associated with leflunomide. ( Bouret, AM; Frances, L; Guijarro, J; Leiva-Salinas, Mdel C; Marin, I, 2013) |
| "Oral squamous cell carcinoma (OSCC) is the most prevalent pathological cancer occurring in the head and neck area." | 1.46 | Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma. ( Cui, H; Fu, G; Qiu, Y; Ren, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ren, A | 1 |
| Fu, G | 1 |
| Qiu, Y | 1 |
| Cui, H | 1 |
| Frances, L | 1 |
| Guijarro, J | 1 |
| Marin, I | 1 |
| Leiva-Salinas, Mdel C | 1 |
| Bouret, AM | 1 |
| Stegeman, H | 1 |
| Kaanders, JH | 1 |
| Verheijen, MM | 1 |
| Peeters, WJ | 1 |
| Wheeler, DL | 1 |
| Iida, M | 1 |
| Grénman, R | 1 |
| van der Kogel, AJ | 1 |
| Span, PN | 1 |
| Bussink, J | 1 |
| Mattar, T | 1 |
| Kochhar, K | 1 |
| Bartlett, R | 1 |
| Bremer, EG | 1 |
| Finnegan, A | 1 |
| Xu, X | 1 |
| Shen, J | 1 |
| Mall, JW | 1 |
| Myers, JA | 1 |
| Huang, W | 1 |
| Blinder, L | 1 |
| Saclarides, TJ | 1 |
| Williams, JW | 1 |
| Chong, AS | 1 |
5 other studies available for leflunomide and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Pro | 2017 |
Multiple eruptive keratoacanthomas associated with leflunomide.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Carcinoma, Squamous Cell; Drug | 2013 |
Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.
Topics: Antineoplastic Agents; Butadienes; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chemor | 2013 |
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Cell | 1993 |
In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
Topics: 3T3 Cells; Adjuvants, Immunologic; Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Squ | 1999 |